NCT Number: NCT00002170
A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)
The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are being treated for MAC.
Looking for future studies?
Notify MeKey information
Conditions
Age range
13 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Univ of California / San Diego Treatment Ctr, San Diego, California, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients must have:
- HIV infection
- New diagnosis of MAC bacteremia and < 7 days of therapy.
Prior Medication:
Allowed:
Patients no more than 7 days of therapy for MAC disease.
Exclusion criteria
Prior Medication:
Excluded:
Prior therapy (or less than 2 weeks) with protease inhibitors other than saquinavir.
Treatment and study plan
Sponsors and collaborators
Lead sponsor
Agouron Pharmaceuticals
Industry
Registry information
Official study title
A Pilot, Phase II, Randomized, Placebo-Controlled Study to Determine the Effects of Viracept on the Clinical Outcome of Disseminated Mycobacterium Avium Complex Disease (MAC) in AIDS Patients Who Are Receiving Standard Acute Treatment for This Opportunistic Infection
Important dates
- First posted
- Aug 31, 2001
- Registry last updated
- Jun 24, 2005
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study to Evaluate the Effects of Azithromycin on MAC Disease Prevention in HIV-Positive Patients
NCT00000947
AIDS-Related Opportunistic Infections, Acquired Immunodeficiency Syndrome
San Francisco, California, United States
View Trial DetailsA Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection
NCT00000895
AIDS-Related Opportunistic Infections, Acquired Immunodeficiency Syndrome
Birmingham, Alabama, United States
View Trial DetailsLong-Term Assessment for Metabolic, Cardiovascular and Neurologic Problems in HIV-Infected Patients With Increased CD4 Cells Counts Following Anti-HIV Therapy
NCT00000883
AIDS-Related Opportunistic Infections, Acquired Immunodeficiency Syndrome
Birmingham, Alabama, United States
View Trial DetailsA Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. Avium Complex (MAC) Infections in Patients With AIDS
NCT00000644
AIDS-Related Opportunistic Infections, Acquired Immunodeficiency Syndrome
Los Angeles, California, United States
View Trial Details